Sensitivity to BST-2 restriction correlates with Orthobunyavirus host range

Mariana Varelaa,⁎, Ilaria M. Pirasa, Catrina Mullanb, Xiaohong Shic, Natasha L. Tilston-Lunela,1, Rute Maria Pintoa,2, Aislynn Taggartb, Stephen R. Welcb,3, Stuart J.D. Neilda, Felix Krehera, Richard M. Elliottd, Massimo Palmariinia

a MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61 1QH, Scotland, United Kingdom
b Department of Infectious Disease, King's College School of Medicine, Guy's Hospital, Great Maze Pond, London Bridge, SE1 9RT London, England, United Kingdom

A B S T R A C T

Orthobunyaviruses include several recently emerging viruses of significant medical and veterinary importance. There is currently very limited understanding on what determines the host species range of these pathogens. In this study we discovered that BST-2/tetherin restricts orthobunyavirus replication in a host-specific manner. We show that viruses with human tropism (Oropouche virus and La Crosse virus) are restricted by sheep BST-2 but not by the human orthologue, while viruses with ruminant tropism (Schmallenberg virus and others) are restricted by human BST-2 but not by the sheep orthologue. We also show that BST-2 blocks orthobunyaviruses replication by reducing the amount of envelope glycoprotein into viral particles egressing from infected cells. This is the first study identifying a restriction factor that correlates with species susceptibility to orthobunyavirus infection. This work provides insight to help us dissect the adaptive changes that bunyaviruses require to cross the species barrier and emerge into new species.

1. Introduction

The increase in travel and commercial trade over the last two decades, in addition to climate and ecological changes, have facilitated the emergence of a variety of pathogenic viruses (Karesh et al., 2012). Several recently emerging viruses belong to the Bunyavirales order (classified until recently simply as the Bunyaviridae family), a large group of enveloped RNA viruses that comprise more than 350 named virus isolates divided among nine virus families and thirteen genera, including some which cause important diseases in humans, livestock and crops (Adams et al., 2017; Ergonul, 2012; McMullan et al., 2012; Yu et al., 2011). Within the Peribunyaviridae, the genus Orthobunyavirus includes more than 170 named viruses some of which are of medical and veterinary importance (Elliott, 2014). The orthobunyavirus genome comprises three segments referred to as large (L), medium (M) and small (S). The large segment encodes for the viral polymerase. The M segment encodes for the viral glycoproteins Gn-NSm-Gc that are synthesized as a polyprotein precursor that is later proteolytically cleaved. The S segment encodes for the viral nucleocapsid and the non-structural protein NSs in an overlapping reading frame (Eifan et al., 2013).

Orthobunyaviruses like Oropouche virus (OROV), La Crosse (LACV) virus and Ngari virus can be the cause of febrile illnesses, encephalitis or hemorrhagic fevers in humans (Bowen et al., 2001; Pinheiro et al., 1981). On the other hand, orthobunyaviruses such as Akabane virus (AKAV), Sathuperi virus (SATV) and the recently emerged Schmallenberg virus (SBV) cause abortions and congenital malformations in ruminants (Calisher, 1996; Kurogi et al., 1975), while Cache Valley virus (CVV) causes disease both in ruminants and humans.

Important public health considerations need to be made when a new orthobunyavirus emerges. For example, SBV emerged in Germany in the summer of 2011 (Hoffmann et al., 2012) and spread very rapidly throughout Europe. On the bases of epidemiological data and the similarity of SBV to other orthobunyaviruses infecting ruminants, the risk of transmission of SBV to humans was considered low. Indeed, subsequent studies showed that no antibodies against this virus were detected in individuals in contact with infected animals (Ducomble et al., 2012; Reusken et al., 2012).
Hence, with some notable exceptions (i.e. CVV), it appears that many of the medically or veterinary relevant orthobunyaviruses have a fairly strict host range as they cause disease either in humans or ruminants.

Virus tropism for a particular animal species is determined by many factors including, in some cases, innate immune responses. Vertebrates have evolved a variety of mechanisms to counteract exposure to pathogens. A key innate immune mechanism to fight virus infection is the type I interferon (IFN) and pro-inflammatory responses. Secretion of IFN by infected cells leads to autocrine and paracrine signaling resulting in the activation of hundreds of IFN-stimulated genes (ISGs) some of which have a direct or indirect antiviral effect (Nan et al., 2014; Yan and Chen, 2012). In turn, viruses have evolved mechanisms to counteract host restriction factors. Available evidence, mainly provided by studies on primate lentiviruses (Wain et al., 2007), suggests that viruses that have successfully established themselves in a given species are able to counteract, at least partially, the innate immune response of the host (Hreczka et al., 2011; Stremlau et al., 2004, 2006). Conversely, the same viruses cannot overcome the innate responses of non-susceptible species. Hence, sequence differences within ISGs orthologues could provide at least partial susceptibility or resistance to a given virus infection.

As most emerging human viruses are predicted to be zoonotic in origin (Mandi et al., 2014), it is important to assess the zoonotic potential of any newly discovered veterinary pathogen. Understanding the molecular mechanisms determining virus host range is key to gain insight into the rules that govern viral emergence. Cross-species transmission requires overcoming host-specific barriers that can be present at each stage of the viral replication cycle and can be specific for different animal species. Our understanding of the effect of host ISGs on bunyavirus host range, as well as the molecular adaptations required to overcome host genetic barriers is limited. In vitro, orthobunyaviruses grow extremely efficiently in a variety of cell lines derived from different species. Hence, the host range of these viruses does not seem to be due to species-specific cellular receptors or other factors absolutely required for virus replication. An ISG with a broad inhibitory activity against enveloped viruses is BST-2 (also known as tetherin, CD317, HML-1,24) (Neil et al., 2008; Sauter, 2014; Van Damme et al., 2008). BST-2 is a type II membrane protein with an unusual topology consisting of a coiled-coiled ectodomain bound to the cell membrane by an N-terminal transmembrane domain and a C-terminal GPI anchor. The BST2 gene is duplicated in ruminants: sheep and cows possess two BST2 paralogs, BST2A and BST2B, both with antiviral properties although probably displaying different mechanisms of action (Murphy et al., 2014; Takeda et al., 2012). Ovine BST2B (oBST2B) displays particular features: it lacks predicted glycosylation sites and a carboxy terminal GPI anchor, resulting in a protein that is retained within the Golgi apparatus (Murphy et al., 2014). In this study, we investigated the role of BST-2 in determining orthobunyavirus host range. We found that BST-2 restricts orthobunyaviruses replication in a species-specific manner and thus likely contributes to determine the host range of this important group of viruses.

2. MATERIALS AND METHODS

2.1. Cell lines

HEK-293T and BSR cells were grown in Dulbecco’s modified Eagle’s medium (DMEM). BSR-T7/5 cells (provided by Karl Conzelmann) were grown in Glasgow modified Eagle’s medium. Sheep choroid plexus cells (CPT-Tert) (Arnaud et al., 2010) were grown in Iscove’s modified Dulbecco’s medium. Human primary dermal fibroblasts were obtained from ATCC and cultured in fibroblast growth media 2 (Promo Cell). All cell lines were supplemented with 10% fetal bovine serum (FBS) and penicillin and streptomycin (p/s) and cultured at 37 °C in a 5% CO2 and 95% humidified atmosphere.

2.2. Antibodies

Antisera used in this study included a rabbit polyclonal antiserum against the SBV N protein (Proteintech) (Varela et al., 2013), a polyclonal antibody against SBV Gc protein (Genscript), a monoclonal antibody against Gc (Wernike et al., 2017) and a polyclonal antibody against whole OROV. Polyclonal antibody against the HA tag was obtained from Abcam. HIV p24 was obtained through the NIH AIDS Reagent Program (HIV-1 p24 Hybridoma (183-H12-5C)) (Chesebro et al., 1992). Antibody against γ-tubulin was obtained from Sigma. Fluorescent secondary antibody included AlexaFlour 488 or 594 goat anti rabbit (Life technologies).

2.3. Viruses

Wild type SBV was obtained by reverse genetics as previously described (Varela et al., 2013). AKAV was rescued by reverse genetics using the plasmids described below. The origin of SATIV was described previously (Watret et al., 1985). OROV was supplied by Christian Drosten (Institute of Virology, Bonn Medical Centre, Bonn, Germany). LACV was supplied by Friedman Weber. The 6V633 strain of CVV was used.

2.4. Plasmids

Plasmids expressing the HA tagged version of human Bst-2 (pCR3.1-bBST2-HA), ovine Bst2-A and -B (pCIoBST2A-HA and pCIoBST2B-HA), an HIV-1 molecular clone deleted of VPU (HIVΔVPU) and plasmid expressing VPU-tagged with the HA epitope have been previously described (Arnaud et al., 2010; McNatt et al., 2009; Neil et al., 2006, 2008), pCI (Promega) was used as an empty plasmid control, pUCSBVST7, pUCSBVM17 and pUCSBVLT7 (Varela et al., 2013) encode the full-length antigenic S, M and L SBV segments and were used to rescue SBV. TVT7R-SBVM-ren [-] encodes a chimeric antigenic SBV M segment where the M protein coding region has been replaced by the Renilla luciferase gene. 2pTM1-SBV-N and 2pTM1-SBV-L express the N and L proteins of SBV under the control of the T7 promoter. pUCAKAVST7, pUCAKAVM17 and pUCAKAVLT7 encode the full-length antigenic proteins S, M and L AKAV segments and were used to rescue AKAV by reverse genetics. Plasmids were synthesized commercially and derived from complete AKAV sequences available in GenBank (AB190458.1; AB100604.1; AB000851.1). The sequences of the chimeric BTS2 genes are presented as Supplemental information (Supplemental experimental procedures 1).

2.5. Concentration of virions

800–900 µl of infected supernatants were filtered, layered over 600 µl of cold 20% sucrose and virions were pelleted by centrifugation at 25,000g for 100 min. Virions were then resuspended in 20 µl of 1 x Laemmli buffer and heated at 95°C for 5 min followed by western blot analysis.

2.6. Recovery of intracellular infectious SBV

Cells were infected at a MOI of 0.001 in triplicate. 48 h post-infection supernatants were removed, cells washed with PBS with 2% FBS and scraped using 500 µl of PBS supplemented with 2% FBS followed by two cycles of freeze-thawing. Cell debris were then pelleted and supernatants titrated by limiting dilution. The experiment was performed three times independently.
2.7. Protease stripping assay

293-hBST2 or control cells were infected with SBV (MOI of 0.001) and 48 h post-infection supernatants were then collected, filtered and virions pelleted as described above. The remaining cells were washed twice with PBS before they were treated with either PBS, dilution buffer (10 mM Tris [pH 8.0], 1 mM CaCl₂, and 150 mM NaCl) or subtilisin A (10 µg/ml dilution buffer) for 45 min at 37°C. The reaction was then stopped by the addition of 10% FBS DMEM and 5 mM of PMSF and supernatants were collected, filtered and virions pelleted as described above. Cells were lysed using 1X Laemmli buffer. Samples were analyzed by western blotting.

2.8. RNA interference

Lentiviral vectors were used to stably express hairpin RNAs against hBST2 or GFP as a control to knockdown BST-2 expression in human primary fibroblasts (Blondeau et al., 2013; Wilson et al., 2007). The relative levels of hBST-2 transcripts were estimated by quantitative RT-PCR sung the Brilliant III Ultra Fast qRT-PCR master mix and the following primers and probe: hBST-FW TGATGGCCCTAATGGCTTCC; hBST-RW AGACCTGGTTTTCTCTTCG; and hBST FAM-CCTCAAGCCTCCTCATTGGTGTCCTT-BBQ. Actin was used as a normalizing control. Reactions were cycled on a Stratagene Mx3005 qPCR System (Agilent Technologies) and data was analyzed with the Mx3000P software. The data is expressed as the Log10 TCID₅₀ per ml of the average of three independent experiments, using two independent virus preparations (paired t-test). (G) Representative experiment showing SBV growth kinetics in 293-hBST2 and control cells transiently transfected with 500 ng of an expression plasmid of HIV-1 VPU or an empty plasmid (pCI) before infection with SBV (MOI 0.001). All the experiments displayed in this figure were done in triplicate and repeated at least three times. *P ≤ 0.05; ** P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

2.9. Quantification of viral mRNA

293-hBST2 and control cells were infected (MOI of 0.001) for 1 h at 4°C to synchronize infection followed by 1.5 h at 37°C. Cells were then cultured for 1, 2 and 5 h when total RNA was extracted using the
RNAeasy mini kit (Qiagen). Viral RNA was reverse transcribed using a SBV specific primer (5′ TTCGGCCCCAGGTGCAAATC 3′) with AccuScript HF reverse transcriptase following manufacturer’s instructions. cDNA was used for qRT-PCR using the Brilliant III Ultra Fast QPCR master mix as indicated by the manufacturer. The following primers and probe were used: SBV-S-FW (TCAGATTGTCATGCTTTGC); SBV-S-RW (TTCGGCCCAAGGTTGGCAAC); and SBV-S-FAM (TTAAGGGATGCACCTGGGCCGATGGC). Reactions were cycled on a Stratagene Mx3005 qPCR System (Agilent Technologies) and data was analyzed with the Mx3000P software.

2.10. Mini replicon assays

SBV mini replicon assays were performed in parallel in 293-hBST2 and 293T-control cells. Cells were transfected with 300 ng of TVT7R-SBVm-ren [-], 300 ng of pTM1-SBV-N, 150 ng of pTM1-SBV-L and 150 ng of pTM1-SBV-L.
250 ng of pCMV-T7 plasmids using Transit-LT1 (Mirus Bio LLC) following the manufacturer’s instructions. 24 h later, luciferase activity was measured using the Dual-Luciferase® Reporter Assays System (Promega). The experiment was performed four times, each time in triplicate.

2.11. Statistical analysis

Statistical analysis was performed using GraphPad Prism. All graphs show the averages and standard deviations.

3. Results

3.1. Human BST-2 restricts SBV replication

Initially, in order to test the sensitivity of orthobunyaviruses to BST-2, we rescued SBV by plasmid transfection of BSR-T7/5 cells in the presence or absence of hBST2. Five days post-transfection, supernatants were collected, virus concentrated by centrifugation and pellets analyzed by western blotting (Fig. 1A). We found a reduction in the amount of SBV nucleocapsid protein (SBV N) in the supernatants of transfected cells suggesting less efficient rescue of SBV in the presence of hBST2. To confirm these results, HEK 293T cells were transiently transfected with a plasmid expressing the hBST2 gene or an empty plasmid as a control and 14 h post-transfection cells were infected with SBV at a low multiplicity of infection (MOI 0.001). Virus replication kinetics was monitored for 72 h. We found decreased SBV infectious titers in samples derived from cells transfected with hBST2 compared to control cells (Fig. 1B-C). We then developed HEK 293T cells stably expressing hBST2 (termed 293-hBST2) by transduction with retroviral vectors carrying hBST2 tagged with the HA epitope or an empty retroviral vector (termed 293-control) as a negative control. As shown in Fig. 1D, all cells expressed hBST2 and, as expected, this cell line was capable of restricting the release of HIV-1 lacking the accessory protein Vpu, a known BST-2 antagonist (Neil et al., 2008) (Fig. 1E). We then compared the SBV replication kinetics in 293-hBST2 and 293-control (Fig. 1F). We found a 10-fold reduction in the titers of SBV produced in 293-hBST2 cells compared to those obtained in 293-control. We obtained the same results using another independently established HEK 293T cell line stably expressing huBST2 (not shown). Importantly, the restriction of SBV in 293-hBST2 cells could be partially overcome by transient transfection of a plasmid expressing HIV-1 Vpu, a known BST2 antagonist (Fig. 1G).

3.2. hBST2 does not affect the early stages of the SBV replication cycle nor the intracellular localization of its nucleocapsid protein

We infected 293-hBST2 and 293-control cells with SBV to address whether hBST2 impacts the early stages of the SBV replication cycle. We then counted the number of infected cells at 8 and 12 h post-infection by immunofluorescence using an antiserum against the SBV N protein. We reasoned that if hBST2 blocks SBV entry, we would find a reduction in the number of virus positive cells early after infection. We found no difference in the number of SBV positive cells between 293-hBST2 and control cells indicating that hBST2 does not impact SBV entry (Fig. S1A). In addition, we found no difference in the intracellular distribution of SBV nucleocapsid (N) protein between 293-hBST2 and 293-control infected cells by confocal microscopy (Fig. S1B).

There was no evidence of accumulation of SBV N at the cell membrane of 293-hBST2 infected cells by confocal microscopy, a typical phenotype observed as a result of BST-2 restriction (Blondeau et al., 2013; Neil et al., 2008; Wang et al., 2014). In order to confirm these data, we performed a protein stripping assay. If hBST2 causes protein tethering on the surface of virus-infected cells we would expect to recover more virions from hBST2-expressing cells than control cells after protease treatment. 293-hBST2 and control cells were infected with SBV and 48 h post-infection virions were stripped from the cell surface by treatment with the protease subtilisin-A. Controls included treatment with PBS and the buffer used for subtilisin-A reconstitution. Interestingly, more virions were recovered from control cells than from hBST2-expressing cells (Fig. 2A).

We then quantified and compared the amount of intracellular infectious virus in 293-hBST2 and 293-control cells. Cells were infected with SBV and after 48 h supernatants were removed and cells lysed by freeze-thawing. Infectious titers of cell-associated SBV particles were measured by endpoint dilution analysis. We found the titers of cell-associated SBV preparations derived from 293-hBST2 lower compared to control cells in each of three independent experiments, although this difference did not reach statistical significance (Fig. 2B). Hence, we also assessed the relative amount of intracellular SBV N in lysates of infected cells by quantitative western blotting. We found a significant reduction in the amount of SBV N in lysates derived from 293-hBST2 compared to control cells (Fig. 2C). To determine if hBST2 induces the degradation of SBV proteins, we repeated the experiments above in the presence or absence of the proteasome inhibitor lactacystin. Lactacystin treatment could not rescue the decrease of SBV N in cell lysates indicating that hBST2 does not induce the degradation of SBV virions via the proteasome (Fig. 2D).

Taken together these results indicate that both the steady-state levels of cell-associated SBV proteins and virions released in the supernatants are reduced in the presence of hBST2. Therefore, we investigated if hBST2 has an impact in the activity of SBV polymerase and/or the formation of the ribonucleoprotein complex (RNP). To this end, 293-hBST2 and 293-control were infected and viral RNA quantified at 1, 2 and 5 h post-infection by qRT-PCR. We found no statistically significant differences in the amount of viral RNAs in cells expressing hBST2 compared to control cells, indicating that hBST2 has no impact on SBV polymerase activity (paired t-test) (Fig. 2E). In addition, we used a mini replica assay for SBV in order to assess viral polymerase activity in either 293-hBST2 and 293-control cells as previously described (Dong et al., 2013). We found no differences in luciferase activity between cells expressing hBST2 and control cells indicating that hBST2 does not impact SBV polymerase activity or the formation of the RNP complex (Fig. 2F).

3.3. hBST2 restricts SBV replication by reducing the amount of envelope glycoproteins in viral particles

Next, we compared the infectivity of SBV virions released into the supernatant of cells expressing hBST2 or control cells. 293-hBST2 and 293-control cells were infected and 48 h later supernatants collected, filtered and the number of viral genomes quantified by qRT-PCR. These supernatants were then used to infect CPT-Tert cells (sheep choroid plexus cells) using 2.5 × 105 of SBV genome equivalents. 8 h post-infection CPT-Tert cells were fixed and analyzed by confocal microscopy using an antibody against SBV N. The number of SBV positive cells was counted and compared between groups. We found a significant decrease in the number of SBV positive cells in CPT-Tert cells infected with 2.5 × 105 genome equivalents of SBV generated in 293-hBST2 compared to those infected with the equivalent amount of genomes generated in 293-control cells (Fig. 3A).

Next, we assessed the relative amount of the Gc SBV glycoprotein present in SBV virions generated in 293-hBST2 and 293-control cells. Virions in supernatants collected from infected cells were pelleted and analyzed by western blot analysis. SBV N and Gc were quantified and the Gc/N ratio calculated (Fig. 3B). We found a significant decrease in the Gc/N ratio in SBV virions produced in 293-hBST2 suggesting that viral envelope protein incorporation is
hampered by hBST2. In order to understand whether the reduced amount of Gc glycoprotein in released virions was the result of a reduced production of Gc in cells stably expressing hBST2 or rather due to the reduced incorporation of Gc into nascent virions, we quantified the amount of Gc in total cell lysates of 293-hBST2 and 293-control cells infected with SBV. To capture the kinetics of Gc expression, we collected lysates early post infection starting from 12 h, which was the earliest time point in which we could detect viral protein expression by western blotting (Fig. 3C). We found statistically significant reduced quantities of Gc glycoprotein in hBST2 cells relative to control cells at all times post infection except at 12 h. At the same time, we quantified the quantities of N and we found that these were also reduced in SBV-infected 293-hBST2 relative to 293-control cells, but the differences reached statistical significance only at 16 h post infection. We also quantified the relative effect of hBST2 on Gc and N expression by estimating the area under the curve (AUC) between 12 and 22 h post infection in 293-control and 293-hBST2. We found a bigger difference in the AUC between 293-hBST2 and 293-control cells for Gc than for N, supporting the idea that hBST2 targets Gc production more effectively.

3.4. BST-2 orthologues restrict orthobunyaviruses in a host-dependent manner

We then monitored the replication kinetics of other ruminant orthobunyaviruses including AKAV and SATV in 293-hBST2 and 293-control cells. We found that hBST2 restricts the replication of AKAV and SATV (approximately 100 fold at 48 hpi), similarly to what we showed for SBV (Fig. 4A). On the other hand, hBST2 is unable to restrict the replication of OROV and LACV, both human orthobunyavirus (Fig. 4A) nor Cache Valley virus (CVV) an orthobunyavirus known to infect both ruminants and humans.

Given that BST-2 might have played a fundamental role in the transmission of pandemic HIV-1 M group from chimpanzees to humans (Sauter et al., 2009) and, as shown above, orthobunyaviruses with ruminant tropism are restricted by hBST2 while orthobunyaviruses with human tropism are not, we asked the question as to whether BST-2 restriction correlates with orthobunyavirus host range. To this end, we developed HEK 293T cell lines stably expressing the ovine orthologues of BST-2 (oBST2A and oBST2B) and assessed the replication kinetics of the bunyaviruses used above. We found that the replication of orthobunyaviruses with only ruminant tropism (SBV,
AKAV and SATV) was not impaired by oBST2A and oBST2B (Fig. 4B). However, the replication of human-tropic OROV and LACV was restricted by the ovine BST2 orthologues (Fig. 4B). As expected the ovine orthologues could not restrict the replication of CVV. The restricted replication of human-tropic OROV and LACV was restricted by sheep BST-2 but not by the ruminant orthologues. In addition, CVV, a virus of both human and ruminant species, was not restricted by either orthologue. We found a correlation between the ability of orthobunyaviruses to replicate in the presence of different BST-2 orthologues in vitro and the range of their susceptible hosts in natural infections. In stable cell lines expressing different BST-2 orthologues, OROV and LACV replication was restricted by sheep BST-2 but not by human BST-2. On the other hand, viruses with ruminant tropism, such as SBV, SATV and AKAV, were restricted by human BST-2 but not by the ruminant orthologues. In addition, CVV, a virus of both humans and ruminants, was not restricted by either orthologue. We found delayed replication of the human virus OROV in primary sheep fibroblasts compared to primary human fibroblasts while the converse was observed with the ruminant orthobunyaviruses SBV, SATV and AKAV. Moreover, knock down of human BST-2 by small hairpin RNA facilitated replication of SBV in primary human fibroblasts.

It is important to stress that orthobunyaviruses encode a non-structural protein (NSs) that inhibits global cellular transcription and therefore the activation of ISGs in general (Elliott, 2014). Hence, it may be counterintuitive to expect that individual ISGs may contribute to determine the host range of orthobunyaviruses considering that these viruses hamper the host antiviral responses by blocking expression of all ISGs. However, some restriction factors such as BST-2 are constitutively expressed in some cell types in addition to being expressed in response to IFN production. These factors are often referred to as part of the “intrinsic” immune response of the host as they are available in the cell even before pathogens are sensed and the IFN response is initiated (Yan and Chen, 2012). Here, we show that BST-2 restricts orthobunyavirus replication in a species-specific manner. In vitro, orthobunyaviruses are able to infect a variety of cell lines of different species. This indicates that the host range of these viruses does not totally depend on receptor availability or other factors required for viral replication. For example, SBV antibodies have been detected in deer, elks, buffalos, alpacas and dogs among others (Lieveart-Peterson et al., 2015) but so far disease has only been documented in ruminants in the form of abortions and congenital malformations. AKAV has been detected in camels, horses, buffalos and dogs but it is only pathogenic

4. Discussion

This is the first study identifying a host determinant of species susceptibility to bunyavirus infection. We showed that orthologues of BST-2, a cellular restriction factor with a broad antiviral activity against enveloped viruses, restrict orthobunyavirus replication in a host-specific manner. We found a correlation between the ability of orthobunyaviruses to replicate in the presence of different BST-2 orthologues in vitro and the range of their susceptible hosts in natural infections. In stable cell lines expressing different BST-2 orthologues, OROV and LACV replication was restricted by sheep BST-2 but not by human BST-2. On the other hand, viruses with ruminant tropism, such as SBV, SATV and AKAV, were restricted by human BST-2 but not by the ruminant orthologues. In addition, CVV, a virus of both humans and ruminants, was not restricted by either orthologue. We found delayed replication of the human virus OROV in primary sheep fibroblasts compared to primary human fibroblasts while the converse was observed with the ruminant orthobunyaviruses SBV, SATV and AKAV. Moreover, knock down of human BST-2 by small hairpin RNA facilitated replication of SBV in primary human fibroblasts.

It is important to stress that orthobunyaviruses encode a non-structural protein (NSs) that inhibits global cellular transcription and therefore the activation of ISGs in general (Elliott, 2014). Hence, it may be counterintuitive to expect that individual ISGs may contribute to determine the host range of orthobunyaviruses considering that these viruses hamper the host antiviral responses by blocking expression of all ISGs. However, some restriction factors such as BST-2 are constitutively expressed in some cell types in addition to being expressed in response to IFN production. These factors are often referred to as part of the “intrinsic” immune response of the host as they are available in the cell even before pathogens are sensed and the IFN response is initiated (Yan and Chen, 2012). Here, we show that BST-2 restricts orthobunyavirus replication in a species-specific manner. In vitro, orthobunyaviruses are able to infect a variety of cell lines of different species. This indicates that the host range of these viruses does not totally depend on receptor availability or other factors required for viral replication. For example, SBV antibodies have been detected in deer, elks, buffalos, alpacas and dogs among others (Lieveart-Peterson et al., 2015) but so far disease has only been documented in ruminants in the form of abortions and congenital malformations. AKAV has been detected in camels, horses, buffalos and dogs but it is only pathogenic
in domestic ruminants (Kirkland, 2015). OROV causes febrile illness in humans but it has also been isolated from primates and sloths (Bastos Mde et al., 2012) while LACV causes encephalitis in humans but no disease presents in chipmunks or squirrels which are also hosts (Reatty and Calisher, 1991; Grimstad, 1988). We found that human BST-2 was unable to restrict replication of OROV and LACV while the ovine orthologues did not restrict the growth of the ruminant viruses SBV, AKAV and SATV. Interestingly, neither the human nor the ruminant BST-2 impaired the replication of CVV which has been associated with abortions and congenital malformations in ruminants as well as encephalitis in humans (Chung et al., 1990; Sexton et al., 1997). These results are in accordance with a previous report which showed that human BST-2 does not restrict the replication of Rift Valley Fever virus, a phlebovirus responsible of congenital abnormalities in ruminants as well as the cause of febrile illness in humans (Radosz et al., 2010).

Under our experimental design we showed that BST-2 does not completely abolish viral replication, in line with the activity of this protein against other enveloped viruses and thus BST-2 proteins of different species likely restrict orthobunyaviruses with different efficiency. However, the role of BST-2 in influencing orthobunyavirus host range will likely derive from a variety of factors including its sites and timing of expression and its efficiency of restriction of a given virus. Ultimately many other factors, including the timing and efficiency of total cellular protein shut-down induced by viral NSs will determine orthobunyaviruses host range.

BST-2 is a versatile molecule that is not only able to restrict replication of a variety of enveloped viruses but it is also implicated in innate sensing, signaling and structural organization of the cell (Sauter, 2014). The most common mechanism of viral restriction by BST-2 described so far involves the physical attachment of virions to the cell membrane of infected cells (Perez-Caballero et al., 2009). However, we previously showed that the ovine orthologue oBST2B restricts sheep retroviruses by reducing the incorporation of envelope glycoprotein into nascent viral particles (Murphy et al., 2014). Here we found that hBST2 restricts SBV replication by reducing the incorporation of the Gc glycoprotein into virions.

The mechanisms by which BST-2 targets orthobunyavirus glycoproteins are not known. However, it does not seem to be the result of a general disruption of viral protein synthesis or turnover by BST-2 given that the same orthologue expressed in the same cell line has a different impact on replication of different orthobunyaviruses. In addition, restriction is not impacted by the addition of inhibitors of the proteasome thus discarding the possibility that BST-2 can induce the degradation of viral proteins. One of the ovine paralogues (oBST2B) lacks a predicted glycosylation site and the carboxy-terminal GPI anchor which results in a protein that is retained within the Golgi apparatus. Bunyaviruses are thought to assemble at membranes of the Golgi apparatus that have been modified by the insertion of the viral glycoproteins. Newly formed viral RNPs locate beneath the modified membranes. It is believed that the interaction between the RNPs and the cytoplasmic tail of either or both the viral glycoproteins triggers budding (Overy et al., 2007; Shi et al., 2007). Thus, crosstalk between orthobunyavirus glycoproteins and BST-2 orthologues may occur in this cellular compartment. However, we found no SBV Gc and hBST2 colocalization in infected cells or expressing SBV Gc by transient transfection indicating that the mechanism of action of hBST2 might be either indirect or involve interaction with another viral protein (i.e. Gn). On the other hand, we cannot assume that glycoproteins from different orthobunyaviruses are translated and traffic in the cytoplasm in exactly the same way. Hence, the species-specificity of BST-2 restriction could be related to differential translation and recruitment of viral proteins for budding.

Emerging infectious diseases pose a threat to human and animal populations. Viral emergence is a multifactorial event where ecological, genetic, immunological and evolutionary processes play a key role in determining its outcome. In general, little is known about the adaptive changes that viruses require to cross the species barrier and emerge into new species (Holmes and Drummond, 2007). Until now, scarce information existed on the host genetic factors that determine orthobunyavirus host range and what rules the emergence of these pathogens. This study provides for the first time clear clues on one of the host genetic barriers that these viruses face to establish themselves in a new host species.

Acknowledgements

This work was supported by the Medical Research Council of the United Kingdom (G0801822)). We would like to thank Sam Wilson and Ben Brennan for useful discussions, Andrew Shaw for providing reagents and Martin Beer for providing the Gc antibody. We would like to dedicate this work to the memory of our friend and colleague Richard M. Elliott.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.virology.2017.06.017.

References


